Edition:
United States

MYnd Analytics Inc (MYND.OQ)

MYND.OQ on NASDAQ Stock Exchange Capital Market

2.16USD
4:00pm EDT
Change (% chg)

$-0.02 (-0.92%)
Prev Close
$2.18
Open
$2.18
Day's High
$2.19
Day's Low
$2.15
Volume
3,901
Avg. Vol
38,197
52-wk High
$5.24
52-wk Low
$1.15

Chart for

About

MYnd Analytics, Inc., formerly CNS Response, Inc., is a predictive analytics company. The Company has developed a decision support tool to help physicians reduce trial and error treatment in mental health, and provide personalized care to patients. The Company provides objective clinical decision support to mental healthcare... (more)

Overall

Beta: -0.05
Market Cap(Mil.): $12.32
Shares Outstanding(Mil.): 5.68
Dividend: --
Yield (%): --

Financials

  MYND.OQ Industry Sector
P/E (TTM): -- 29.39 33.88
EPS (TTM): -2.49 -- --
ROI: -630.73 7.75 13.21
ROE: -816.86 11.07 15.18

BRIEF-Mynd Analytics Provides Qtrly Revenue $459,900 Versus $31,900

* MYND ANALYTICS PROVIDES BUSINESS UPDATE AND REPORTS SIGNIFICANT INCREASE IN REVENUES FOR THE SECOND QUARTER OF 2018

May 15 2018

BRIEF-MYnd Completes Private Placement By Company Insiders At Significant Premium To Market 

* MYND COMPLETES $2.1 MILLION DOLLAR PRIVATE PLACEMENT BY COMPANY INSIDERS AT SIGNIFICANT PREMIUM TO MARKET Source text for Eikon: Further company coverage:

Apr 03 2018

BRIEF-Mynd Analytics Inc Files For Stock Shelf Of Upto $75 Million

* MYND ANALYTICS INC FILES FOR STOCK SHELF OF UPTO $75 MILLION Source text: (http://bit.ly/2BOol6H) Further company coverage:

Feb 23 2018

BRIEF-MYnd Analytics Awarded Canadian Patent On Neuromodulation Platform Predicts Patients Likely To Respond To TMS For Treating Depression

* MYND ANALYTICS AWARDED CANADIAN PATENT ON NEUROMODULATION PLATFORM; PREDICTS PATIENTS LIKELY TO RESPOND TO TMS FOR TREATING DEPRESSION Source text for Eikon: Further company coverage:

Feb 08 2018

Earnings vs. Estimates